Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00102648
Other study ID # 2004-0424
Secondary ID NCI-2012-01311NC
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date December 21, 2004
Est. completion date December 1, 2022

Study information

Verified date December 2021
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lonafarnib together with temozolomide may kill more tumor cells.


Description:

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule. II. To describe the toxicities of the Sarasar and Temodar combination treatment using this dosing schedule. III. To evaluate response as measured by 6-month progression-free survival and objective tumor response. OUTLINE: This is a dose-escalation study of lonafarnib. Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and lonafarnib PO twice daily (BID) on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 35
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with histologically proven supratentorial glioblastoma multiforme (GBM) or gliosarcoma - Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) scan after radiation therapy; the scan done prior to study entry documenting progression will be reviewed by the treating physician to document tumor volume changes to provide a gross assessment of growth rate - Patients may have had as many as 2 prior chemotherapy regimens for recurrent or progressive tumor; patients must have had prior treatment with Temodar but may not have had prior treatment with farnesyl transferase inhibitors (Sarasar or Zarnestra); patients in phase 1b expansion are required to have received a minimum of two cycles of adjuvant temozolomide (TMZ) - All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital - Patients must have shown unequivocal evidence for tumor progression by MRI or computed tomography (CT) scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement - Patients (pts) having had recent resection of recurrent or progressive tumor are eligible as long as: - Patients must be status post surgical resection at least 2 weeks prior to study enrollment, have recovered from surgery, have adequate early wound healing and a Karnofsky performance status of > or = 60 - Residual disease following resection of recurrent tumor is not mandated for eligibility into the study; a CT/MRI should be done within 96 hours (hrs) post-op or at least 4 weeks (wks) post-op (within 14 days of registration); if the steroid dose is increased between the scan date and registration, a new baseline MRI/CT is required on a stable steroid dose for 5 days - Patients must have a Karnofsky performance status of >= 60 - Patients must have recovered from the toxic effects of prior therapy: 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the study chair - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count of >= 100,000/mm^3 - Serum glutamic pyruvate transaminase (SGPT) < 2.5 times normal - Alkaline phosphatase < 2.5 times normal - Bilirubin < 1.5 mg - Blood urea nitrogen (BUN) < 1.5 times institutional normal - Creatinine < 1.5 times institutional normal Exclusion Criteria: - Patients must not be taking primidone, carbamazepine, phenobarbital or phenytoin anticonvulsants; patients changing from these anticonvulsants to other allowable drugs that are not enzyme inducing antiepileptic drugs (EIAEDs) must be off the drugs listed above for at least 72 hours prior the initiation of treatment - Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), are ineligible unless in complete remission and off of all therapy for that disease for a minimum of 3 years - Patients must not have: - Uncontrolled active infection - Disease that will obscure toxicity or dangerously alter drug metabolism - Serious intercurrent medical illness - Prior recurrence with a farnesyl transferase inhibitor - Oral contraceptives and other hormonal methods (Depo-Provera) of birth control

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lonafarnib
Given PO
Temozolomide
Given PO

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of lonafarnib when given with temozolomide, defined as the dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) 28 days
Primary Tolerability of regimen in patients with disease progression or recurrence during or after recent completion of treatment with temozolomide Up to 11 years
Secondary Progression free survival (PFS) In the historical dataset, the proportion of patients remaining alive and free from progression at 6 months was 15% (95% confidence interval for ranged from 10% to 19%). We will set p0 to 15% and we will set p1 to 30% (looking for a doubling of the 6-month PFS rate). Based on these design parameters, a two-stage design would require that at least 4 of the initial 19 patients are without progression at 6 months. 6 months
Secondary Objective response Up to 11 years
Secondary Overall survival Up to 11 years
Secondary Treatment-related toxicities Treatment-related toxicity data will be collected and described. Up to 11 years
See also
  Status Clinical Trial Phase
Recruiting NCT05577091 - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma Phase 1
Recruiting NCT05284643 - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma N/A
Recruiting NCT05039281 - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT04988750 - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients N/A
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT00503204 - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Phase 1
Completed NCT03216499 - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Phase 2
Not yet recruiting NCT04717999 - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma N/A
Not yet recruiting NCT05540275 - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma Phase 2
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Recruiting NCT04888611 - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma Phase 2
Completed NCT00390299 - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05463848 - Surgical Pembro +/- Olaparib w TMZ for rGBM Phase 2
Active, not recruiting NCT04479241 - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma Phase 2
Active, not recruiting NCT00777153 - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Phase 3
Withdrawn NCT05017610 - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Early Phase 1
Recruiting NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1
Active, not recruiting NCT05324501 - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma Phase 1
Withdrawn NCT05666349 - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma Phase 1

External Links